SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting overwhelmingly positive Phase 2 clinical trial results for sonelokimab in axial spondyloarthritis, demonstrating significant efficacy and potential disease modification ahead of its Investor Day. Despite this "game-changing" data and the company's strong cash runway, the community is actively discussing market "sell the news" behavior and perceived manipulation amidst significant short interest.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as reports surface of unsolicited takeover interest from rivals, some eyeing the entire company while others target specific assets like Venmo or Braintree following its significant stock slump. The community is actively debating potential buyers and buyout prices, largely driven by the belief that the fintech giant is fundamentally undervalued given its substantial free cash flow and ongoing share buyback program.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection until 2044 for treating bipolar I disorder and schizophrenia. The community is actively debating the stock's significant undervaluation given this second recent approval, speculating on a potential buyout by larger pharmaceutical companies.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike faces a sharp sell-off across the cybersecurity sector, driven by market fears that Anthropic's new AI code security tool will disrupt traditional offerings. The community is fiercely debating whether this is an irrational overreaction, with many highlighting CRWD's distinct endpoint and cloud security services and arguing that AI-driven threats will actually increase demand for established cybersecurity leaders.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is a major talking point as its impending earnings report follows recent news of a 12% workforce reduction, fueling intense community debate over the stock's persistent new all-time lows and the company's financial outlook in the competitive EV sector.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point as President Trump files a $5 billion lawsuit against the bank and CEO Jamie Dimon, alleging politically motivated account closures, a move that follows Dimon's public criticism of Trump's proposed credit card rate cap and fuels community debate over broader financial sector pressures.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is facing intense selling pressure, hitting new lows, as the cybersecurity sector grapples with fears that AI tools like Anthropic's Claude Code Security could disrupt existing solutions, prompting community debate between panic selling and 'buy the dip' opportunities ahead of its earnings report.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF ($IGV) is experiencing a significant sell-off and hitting new lows, fueled by widespread community fear that Anthropic's Claude AI tools will disrupt and replace traditional software. This "SaaS-pocalypse" is sparking intense debate among investors over whether the market's aggressive reaction is an overblown narrative or a fundamental threat.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit (INTU) is a hot topic as it experiences a dramatic sell-off, with its stock plummeting due to widespread market fears that generative AI will significantly disrupt its core tax and accounting software businesses. Community discussion, however, is sharply divided, with many viewing the heavily oversold conditions as a prime buying opportunity, believing AI will enhance rather than replace Intuit's strong ecosystem ahead of its upcoming earnings.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is surging after Novo Nordisk's weight-loss drug CagriSema underperformed Eli Lilly's tirzepatide, intensifying speculation that Viking's VK2735, a dual GLP-1/GIP agonist with strong tolerability, is now an even more critical acquisition target for major pharma amid a significant short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q1 Earnings Forecast for Genmab A/S Issued By HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Equities researchers at HC Wainwright dropped their Q1 2026 earnings per share estimates for Genmab A/S in a report released on Wednesday...

Genmab A/S (NASDAQ:GMAB) Announces Earnings Results

Genmab A/S (NASDAQ:GMAB - Get Free Report) posted its earnings results on Tuesday. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.46...

Genmab A/S (NASDAQ:GMAB) Price Target Raised to $40.00 at HC Wainwright

HC Wainwright lifted their target price on Genmab A/S from $39.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday...

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) have earned an average rating of "Moderate Buy" from the ten research firms that are covering the stock, MarketBeat.com reports. One...

Genmab A/S Q4 Earnings Call Highlights

Genmab A/S (NASDAQ:GMAB) executives told investors the company delivered on its 2025 priorities of accelerating late-stage pipeline development, maximizing commercial medicines, and executing its...

Genmab A/S (OTCMKTS:GNMSF) Posts Quarterly Earnings Results

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.55 EPS for the quarter. Genmab A/S had a return on equity of 23.98% and a net...

Genmab A/S (NASDAQ:GMAB) Coverage Initiated at Jefferies Financial Group

Jefferies Financial Group assumed coverage on Genmab A/S in a report on Tuesday. They set a "buy" rating and a $41.50 price target for the company...

Morgan Stanley Reaffirms "Equal Weight" Rating for Genmab A/S (NASDAQ:GMAB)

Morgan Stanley reaffirmed an "equal weight" rating and set a $34.00 target price on shares of Genmab A/S in a report on Monday...

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Sees Significant Decrease in Short Interest

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) was the target of a large decline in short interest in January. As of January 30th, there was short interest totaling 8,413,829 shares, a...

279,932 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Cibc World Market Inc.

Cibc World Market Inc. purchased a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the third quarter, according to its most recent Form 13F filing with the...

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Current Price	$29.22
Prev Close	$29.29
Open	$28.48
Dividend Yield	0.00%
50-Day Moving Average	$32.15
Beta	0.63
Avg. Volume	2M
PE Ratio	18.78

52-Week High	$35.43
52-Week Low	$17.24
Market Capitalization	$18.05B
EPS (Annual)	$1.55
Price to Book	3.09
Revenue Per Employee	$1.23M

GMAB
Genmab - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GMAB News

GMABGenmab - ADR